SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA (SOPH) reported that Chief Executive Officer and director Ross Muken sold 422 Ordinary Shares on September 21, 2026 at $8.33 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations from restricted stock units that vested on September 18, 2026, under a pre-established Rule 10b5-1(c) trading plan, and are not discretionary trades. Following this transaction, Muken directly holds 670,229 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) received a notice that officer George Cardoza intends to sell 774 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC Executive Financial Services, with the securities originating from Restricted Stock Units granted by the issuer on September 18, 2026.
The notice also reports prior 10b5-1 sales during the past three months: 1,592 shares of common stock sold on July 6, 2026 for $8,419.45, and 774 shares sold on June 22, 2026 for $4,163.73.
SOPHiA GENETICS SA (SOPH) received a notice under Rule 144 from Ross J. Muken regarding a proposed sale of 422 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The filing also lists prior Rule 10b5-1 plan sales of common shares in recent months.
SOPHiA GENETICS SA (SOPH) reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on September 14, 2026 in an open-market or private transaction at a weighted average price of $7.8833 per share, pursuant to a duly adopted Rule 10b5-1(c) trading plan, leaving him with 208,387 shares held directly.
SOPHiA GENETICS SA (SOPH) reports that Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares on September 14, 2026 at a weighted average price of about $7.88 per share, in transactions executed under a duly adopted Rule 10b5-1(c) trading plan, leaving him with 552,887 shares held directly.
SOPHiA GENETICS SA (SOPH) reported that its Chief Legal Officer, Daan Van Well, sold 6,168 ordinary shares on September 11, 2026 in an open-market or private transaction. The weighted average sale price was about $7.63 per share, with individual trades between $7.55 and $7.85. After this sale, the officer directly held 338,884 ordinary shares. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.
SOPHiA GENETICS SA (SOPH) reported that Executive Chairman Jurgi Camblong sold 8,500 Ordinary Shares on September 10, 2026 in an open-market transaction at a weighted average price of about $7.66 per share, under a duly adopted Rule 10b5-1(c) trading plan. Following this sale, he directly holds 3,435,822 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) received a notice that Daan Guido Maria Van Well, an officer, intends to sell up to 6,168 shares of Common Stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were acquired from the issuer upon vesting of restricted stock units on July 2 and July 3, 2026.
The notice lists an aggregate market value of $46,938.48 for the securities to be sold and identifies NASDAQ as the trading market. The RSUs were originally granted by the issuer and the planned sale is for the officer’s account.
SOPHiA GENETICS SA (SOPH) director Kathy L. Hibbs reported selling 6,250 Ordinary Shares on September 8, 2026. The shares were sold at a weighted average price of $8.1308 per share in transactions ranging from $7.90 to $8.35, under a duly adopted Rule 10b5-1(c) trading plan. Following this sale, she directly holds 96,992 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 27, 2026 in an open-market or private transaction under a Rule 10b5-1(c) trading plan. The weighted average sale price was $8.9096 per share, and Xu now holds 556,887 Ordinary Shares directly.